PARIS (Reuters)—Sanofi SA will be able to provide millions of doses of hydroxychloroquine (HCQ) for patients with the illness caused by the novel coronavirus if the old malaria drug proves successful in clinical trials, its chief executive tells Reuters on Thursday.
Paul Hudson, who became CEO of the French drugmaker in September, said in an interview that the company is currently manufacturing at over 93% capacity during the pandemic.
He says the company had made a choice to overproduce its drugs to ensure supplies for hospitals in Europe and the U.S. facing an unprecedented crush of patients suffering from respiratory complications that is threatening to overwhelm healthcare systems.
Hospital executives and doctors from nine European countries, in an open letter on Wednesday, said they only had up to two weeks worth of some medicines used in intensive care units and urged greater European collaboration.
E.U. countries will have access to the medicines they need, the bloc’s industry chief Thierry Breton said on Thursday in an attempt to reassure the public.
Hudson said Sanofi was not at full manufacturing capacity because workers with coronavirus symptoms such as fever, and any employee who had been in close contact with them, are sent home for two weeks.
“We are overly cautious. One person getting a temperature means we lose maybe a half dozen people,” he says.
Sanofi operates 73 industrial locations in 32 countries.
“More than 80% of the medicines we make are considered essential. So, you know, everywhere we are working, we are pretty much working every hour,” Hudson said.
The company began manufacturing as much HCQ as it could in February, after Chinese data suggested the malaria drug could help some patients with COVID-19. Sanofi sells the drug, which has been in use since the 1950s, under the brand name Plaquenil in some countries.
The new coronavirus emerged in China in December and has since spread around the world. It has infected over 1 million people globally and killed more than 51,400.
Surge in Demand
Sanofi is also developing two potential vaccines against the coronavirus, and is testing the rheumatoid arthritis drug Kevzara (sarilumab) it sells in partnership with Regeneron Pharmaceuticals Inc. as a potential COVID-19 treatment.
Demand for HCQ surged after U.S. President Donald Trump touted it as a potential “game changer” for the pandemic and U.S. regulators have since authorized its emergency use for coronavirus patients.
But the small Chinese trial had many limitations and the European Commission has said there is no evidence yet that the drug is effective for coronavirus patients.
Sanofi has fielded requests for the drug, which is also used to treat lupus and rheumatoid arthritis, from countries all over the world, Hudson said.
He added that Sanofi is working with other companies to make sure the supply of HCQ is as broad as possible.
“We just tried to coordinate a little bit to say to companies, ‘Let’s all not end up supplying the same market. Let’s make sure that everybody has a chance that needs it,'” Hudson says. If one area is well supplied, he added, “then we’re happy to help somewhere else.”
There is still much to learn about who is most likely to be helped by the drug and at what dose before companies can accurately estimate supply demand if the treatment proves effective.
“It’s important to know whether you would give it to mild patients or severe patients,” Hudson explains. “The sheer volume difference in those patients is significant.”
